Argon beam coagulation as adjuvant treatment after curettage of aneurysmal bone cysts

A preliminary study

Judd E. Cummings, Richard Smith, Robert Heck

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The optimal treatment of aneurysmal bone cysts remains an area of debate. Curettage, with or without adjuvant therapy, has been advocated for tumors in most locations. To evaluate argon beam coagulation as adjuvant therapy to curettage, we retrospectively analyzed the complication and recurrence rates in 40 consecutive patients with a diagnosis of aneurysmal bone cyst. For our analysis of recurrence, we excluded six of the 40 patients who were lost to followup or had less than 18 months followup; five patients treated with resection also were excluded. Of the remaining 29 patients, 17 were treated with curettage and argon beam coagulation and 12 were treated with curettage with or without phenol. None of the 17 patients treated with curettage and argon beam coagulation had a recurrence, whereas four patients treated without argon beam coagulation had recurrences. There were no differences between patients treated with or without argon beam coagulation regarding frequencies of intraoperative complications, neurovascular injury, or bone graft incorporation. Argon beam coagulation seems to offer favorable control rates when compared with curettage with or without phenol. No complications have been experienced thus far with its use. Level of Evidence: Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

Original languageEnglish (US)
Pages (from-to)231-237
Number of pages7
JournalClinical Orthopaedics and Related Research
Volume468
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Argon Plasma Coagulation
Aneurysmal Bone Cysts
Curettage
Recurrence
Phenol
Therapeutics
Intraoperative Complications
Guidelines
Transplants
Bone and Bones
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Argon beam coagulation as adjuvant treatment after curettage of aneurysmal bone cysts : A preliminary study. / Cummings, Judd E.; Smith, Richard; Heck, Robert.

In: Clinical Orthopaedics and Related Research, Vol. 468, No. 1, 01.01.2010, p. 231-237.

Research output: Contribution to journalArticle

@article{cc0eb23436744fb281d5919ec788fded,
title = "Argon beam coagulation as adjuvant treatment after curettage of aneurysmal bone cysts: A preliminary study",
abstract = "The optimal treatment of aneurysmal bone cysts remains an area of debate. Curettage, with or without adjuvant therapy, has been advocated for tumors in most locations. To evaluate argon beam coagulation as adjuvant therapy to curettage, we retrospectively analyzed the complication and recurrence rates in 40 consecutive patients with a diagnosis of aneurysmal bone cyst. For our analysis of recurrence, we excluded six of the 40 patients who were lost to followup or had less than 18 months followup; five patients treated with resection also were excluded. Of the remaining 29 patients, 17 were treated with curettage and argon beam coagulation and 12 were treated with curettage with or without phenol. None of the 17 patients treated with curettage and argon beam coagulation had a recurrence, whereas four patients treated without argon beam coagulation had recurrences. There were no differences between patients treated with or without argon beam coagulation regarding frequencies of intraoperative complications, neurovascular injury, or bone graft incorporation. Argon beam coagulation seems to offer favorable control rates when compared with curettage with or without phenol. No complications have been experienced thus far with its use. Level of Evidence: Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.",
author = "Cummings, {Judd E.} and Richard Smith and Robert Heck",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/s11999-009-0914-7",
language = "English (US)",
volume = "468",
pages = "231--237",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Argon beam coagulation as adjuvant treatment after curettage of aneurysmal bone cysts

T2 - A preliminary study

AU - Cummings, Judd E.

AU - Smith, Richard

AU - Heck, Robert

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The optimal treatment of aneurysmal bone cysts remains an area of debate. Curettage, with or without adjuvant therapy, has been advocated for tumors in most locations. To evaluate argon beam coagulation as adjuvant therapy to curettage, we retrospectively analyzed the complication and recurrence rates in 40 consecutive patients with a diagnosis of aneurysmal bone cyst. For our analysis of recurrence, we excluded six of the 40 patients who were lost to followup or had less than 18 months followup; five patients treated with resection also were excluded. Of the remaining 29 patients, 17 were treated with curettage and argon beam coagulation and 12 were treated with curettage with or without phenol. None of the 17 patients treated with curettage and argon beam coagulation had a recurrence, whereas four patients treated without argon beam coagulation had recurrences. There were no differences between patients treated with or without argon beam coagulation regarding frequencies of intraoperative complications, neurovascular injury, or bone graft incorporation. Argon beam coagulation seems to offer favorable control rates when compared with curettage with or without phenol. No complications have been experienced thus far with its use. Level of Evidence: Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

AB - The optimal treatment of aneurysmal bone cysts remains an area of debate. Curettage, with or without adjuvant therapy, has been advocated for tumors in most locations. To evaluate argon beam coagulation as adjuvant therapy to curettage, we retrospectively analyzed the complication and recurrence rates in 40 consecutive patients with a diagnosis of aneurysmal bone cyst. For our analysis of recurrence, we excluded six of the 40 patients who were lost to followup or had less than 18 months followup; five patients treated with resection also were excluded. Of the remaining 29 patients, 17 were treated with curettage and argon beam coagulation and 12 were treated with curettage with or without phenol. None of the 17 patients treated with curettage and argon beam coagulation had a recurrence, whereas four patients treated without argon beam coagulation had recurrences. There were no differences between patients treated with or without argon beam coagulation regarding frequencies of intraoperative complications, neurovascular injury, or bone graft incorporation. Argon beam coagulation seems to offer favorable control rates when compared with curettage with or without phenol. No complications have been experienced thus far with its use. Level of Evidence: Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

UR - http://www.scopus.com/inward/record.url?scp=73449101832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449101832&partnerID=8YFLogxK

U2 - 10.1007/s11999-009-0914-7

DO - 10.1007/s11999-009-0914-7

M3 - Article

VL - 468

SP - 231

EP - 237

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 1

ER -